3.3 Safety
nausea, palpitations, hepatotoxicity, skin rash, myopathy, arthralgia
ADVERSE EVENTS, MYOPATHY, ADVERSE EVENT
Six out of 29 [20.7%] patients discontinued mercaptopurine due to adverse events that were considered to be related to the study drug: four patients stopped mercaptopurine treatment due to nausea, one due to hepatotoxicity and one due to arthralgia. One patient discontinued mercaptopurine due to an adverse event [i.e. hospitalization due to corticosteroid-induced myopathy], which was not considered to be related to mercaptopurine treatment. Placebo was discontinued by two out of 30 [6.7%] patients due to adverse events that were considered to be related to the study drug: one patient due to palpitations and the other patient due to a skin rash.Except for one patient in the placebo group, all patients experienced at least one adverse event during the study [Safety data


Prevalence of adverse events in the mercaptopurine and placebo group per month. The number on the 